Xin Lang Cai Jing·2025-08-29 00:46Group 1 - The company reported a revenue of 1.1 billion yuan (+48%) for the first half of 2025, with a net loss attributable to shareholders of 450 million yuan, meeting expectations [1] - Core products are experiencing continuous growth, with over 1,000 hospitals approved for both autoimmune and oncology treatments. The commercialization team for autoimmune diseases has approximately 900 members, while the oncology team has over 500 members [1] - The company successfully licensed Tai'tasip for the treatment of myasthenia gravis to Vor Bio, receiving an upfront payment of 45 million USD and potential milestone payments totaling up to 4.105 billion USD [2] Group 2 - The company licensed RC28 to Santen China, receiving an upfront payment of 250 million yuan and potential milestone payments totaling up to 525 million yuan [3] - The company expects revenues of 2.21 billion, 2.95 billion, and 4.26 billion yuan for the years 2025, 2026, and 2027, respectively, driven by the continued growth of Tai'tasip and Vidi'simab [3]